Neuroimaging Findings in Patients With COVID-19
Correlation of Neuroimaging Findings With Clinical Presentation and Laboratory Data in Patients With COVID-19: A Single Center Study
1 other identifier
observational
436
1 country
1
Brief Summary
This study aimed to discuss the neuroimaging findings and indications, epidemiological data, laboratory values, and the relationship of these variables with mortality in patients with COVID-19.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2020
CompletedFirst Submitted
Initial submission to the registry
January 29, 2021
CompletedFirst Posted
Study publicly available on registry
February 2, 2021
CompletedFebruary 4, 2021
February 1, 2021
9 months
January 29, 2021
February 1, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Frequency of acute thromboembolism in COVID-19 patients undergoing neuroimaging
Acute thromboembolic events are common in COVID-19 subjects undergoing neuroimaging, potentially due to an increased procoagulant process.
Between April and December 2020
Study Arms (4)
Group 1
The first group consisted of 46 patients whose neuroimaging findings demonstrated acute/subacute infarction, bleeding, encephalitis, and venous sinus thrombosis
Group 2
The 2nd group (N=390) was obtained by subtracting the 1st group from all cases.
Group 3
The third group (N = 189) consisted of patients of the first group and patients with chronic ischemic changes observed in neuroimaging
Group 4
The 4th group (N=247) was obtained by subtracting the 3rd group from all cases.
Interventions
MR and BT Imaging
Eligibility Criteria
Subjects more than 18 years old and who are followed up and treated with the diagnosis of COVID-19 in Sağlık Bilimleri Üniversitesi Gazi Yaşargil Training and Research Hospital will be included.
You may qualify if:
- COVID-19 RT-PCR positivity-
- older than 18 years old
You may not qualify if:
- younger than 18 years old
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Sağlik Bilimleri Üniversitesi Training and Research Hospital
Diyarbakır, 21070, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
ŞEYHMUS KAVAK, MD
SAGLIK BİLİMLERİ ÜNİVERSİTESİ TRAINING AND RESEARCH HOSPITAL H
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, Radiologist
Study Record Dates
First Submitted
January 29, 2021
First Posted
February 2, 2021
Study Start
April 1, 2020
Primary Completion
December 31, 2020
Study Completion
December 31, 2020
Last Updated
February 4, 2021
Record last verified: 2021-02